Use of Hydroxocobalamin (Vitamin B12a) in Patients With Vasopressor Refractory Hypotension After Cardiopulmonary Bypass: A Case Series

Sarah Armour, Trygve K. Armour, William R. Joppa, Simon Maltais, James A. Nelson, Erica Wittwer

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Hydroxocobalamin (vitamin B12a) is an emerging treatment for vasoplegic syndrome (VS) associated with cardiopulmonary bypass (CPB). Given its cost and scarcity, an institutional guideline for its use as a rescue treatment in cases of suspected VS was developed. Hemodynamic variables and vasopressor requirements were reviewed for a series of 24 post-CPB patients who received B12a. Favorable changes in hemodynamic parameters and vasopressor requirements were seen after B12a administration although guideline criteria for VS were inconsistently met. These findings support the continued study of B12a in patients with CPB-associated VS.

Original languageEnglish (US)
JournalAnesthesia and analgesia
Volume129
Issue number1
DOIs
StatePublished - Jul 1 2019

    Fingerprint

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this